Patents by Inventor Edward D. Mihelich

Edward D. Mihelich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazoles as human non-pancreatic secretory phospholipase A.sub.2 inhibitors
    Patent number: 5972972
    Abstract: A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: October 26, 1999
    Assignee: Eli Lilly and Company
    Inventors: Edward D. Mihelich, Tulio Suarez, Gary A. Hite, Peter J. Doman, Stuart E. Willetts
  • N-hydroxy-N-[3-[2-(halophenylthio)phenyl]prop-2-enyl]ureas as lipoxygenase inhibitors
    Patent number: 5283361
    Abstract: This invention relates to N-hydroxy-N-[3-[2-(4'-halophenylthio)phenyl]prop-2-enyl]ureas, formulations containing those compounds and methods of using such compounds as 5-lipoxygenase inhibiting agents.
    Type: Grant
    Filed: April 8, 1992
    Date of Patent: February 1, 1994
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Hite, Edward D. Mihelich, David W. Snyder, Tulio Suarez
  • N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas useful as 5-lipoxygenase inhibiting agents
    Patent number: 5130485
    Abstract: This invention relates to N-hydroxy-N-[3-(2-substituted phenyl)prop-2-enyl]ureas and thioureas, formulations containing those compounds, and methods of using such compounds as 5-lipoxygenase inhibiting agents.
    Type: Grant
    Filed: April 23, 1991
    Date of Patent: July 14, 1992
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Hite, Edward D. Mihelich, David W. Snyder, Tulio Suarez
  • 5-Lipoxygenase inhibitors
    Patent number: 5028629
    Abstract: This invention relates to 2-(substituted)-N-hydroxy-N-alkylcinnamamides of the formula: ##STR1## where R.sup.1 is C.sub.1 -C.sub.4 alkyl;n is 0 or 1;R.sup.2 is trifuloromethyl, C.sub.1 -C.sub.10 alkyl, phen(C.sub.1 -C.sub.4)alkylene or ##STR2## where m is 0, 1 or 2 and R.sup.3 is C.sub.1 -C.sub.4 alkyl; X is C.sub.1 -C.sub.6 alkyl, phenyl, phen(C.sub.1 -C.sub.4)alkylene where the phenyl ring is unsubstituted or monosubstituted with --S(O).sub.m --R.sup.3 and m and R.sup.3 are as defined above, or ##STR3## where m is 0, 1 or 2 and R.sup.4 is C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, or unsubstituted or monosubstituted C.sub.1 -C.sub.20 alkyl where the substituent is CF.sub.3, C.sub.3 -C.sub.8 cycloalkyl, or phenyl,or a pharmaceutically acceptable salt thereof; formulations containing those compounds and methods of using such compounds as 5-lipoxygenase inhibiting agents.
    Type: Grant
    Filed: March 28, 1990
    Date of Patent: July 2, 1991
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Hite, Edward D. Mihelich, Tulio Suarez
  • Furanone derivatives
    Patent number: 4874782
    Abstract: This invention provides certain furanone derivatives, their pharmaceutical formulations, and their use in a method for treating inflammation, asthma, or allergies.
    Type: Grant
    Filed: June 26, 1987
    Date of Patent: October 17, 1989
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Christopher J. M. Meade, Edward D. Mihelich, Michael L. Phillips
  • Novel prostaglandin analogues and process for making same
    Patent number: 4496759
    Abstract: A novel process for the oxidation of olefins to the corresponding alpha-epoxy alcohols which can be incorporated in the total synthesis of members of a novel class of prostaglandin analogues.Olefins are reacted with singlet oxygen in the presence of a group IVB, VB or VIB transition metal catalysts, excluding chromium. The reaction is fast and highly selective to the alpha-epoxy alcohol. When cyclopentene is oxidized in the process of the invention, high yields of cis 2,3-epoxy cyclopentan-1-01-are obtained. The latter compound is used as a starting material in the synthesis of prostaglandin analogues. The prostanoids of the invention are characterized by an oxa group replacing the methylene group at the 7-position, and the absence of a hydroxyl or other substituent at the 11-position.Members of this class of prostanoids show important cytoprotective properties in animal tests.
    Type: Grant
    Filed: May 5, 1982
    Date of Patent: January 29, 1985
    Assignee: The Procter & Gamble Company
    Inventor: Edward D. Mihelich
  • Novel prostaglandin analogues and process for making same
    Patent number: 4345984
    Abstract: A novel process for the oxidation of olefins to the corresponding alpha-epoxy alcohols which can be incorporated in the total synthesis of members of a novel class of prostaglandin analogues.Olefins are reacted with singlet oxygen in the presence of a group IVB, VB or VIB transition metal catalyst, excluding chromium. The reaction is fast and highly selective to the alpha-epoxy alcohol. When cyclopentene is oxidized in the process of the invention, high yields of cis 2,3-epoxy-cyclopentan-1-ol are obtained. The latter compound is used as a starting material in the synthesis of prostaglandin analogues. The prostanoids of the invention are characterized by an oxa group replacing the methylene group at the 7-position, and the absence of a hydroxyl or other substituent at the 11-position.Members of this class of prostanoids show important cytoprotective properties in animal tests.
    Type: Grant
    Filed: March 2, 1981
    Date of Patent: August 24, 1982
    Assignee: The Procter & Gamble Company
    Inventor: Edward D. Mihelich